Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238
Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM. Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2024 Apr;22(2):115-125.e. doi: 10.1016/j.clgc.2023.09.009
Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review. Clin Genitourin Cancer. 2023 Aug;21(4):459-66. doi: 10.1016/j.clgc.2023.03.011
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Chen ZX, Hohmann L, Banjara B, Zhao Y, Diggs K, Westrick SC. Recommendations to protect patients and health care practices from Medicare and Medicaid fraud. J Am Pharm Assoc. 2020 Nov;60(6):e60-5. doi: 10.1016/j.japh.2020.05.011
Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clin Genitourin Cancer. 2013 Jun;11(2):161-7. doi: 10.1016/j.clgc.2012.10.003
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Andrews EB, Gilsenan A, Cook SF. Therapeutic Risk Management Interventions: feasibility and Effectiveness. J Am Pharm Assoc. 2004 Jan 1;44(4):491-500.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2